TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Studies of Non-Alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Although a liver biopsy is necessary to make the diagnosis of NASH, patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes have been ruled out are eligible to participate.~ 2. Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.~ 3. Depending on their willingness to participate, subjects may enroll in DNA laboratory-only or clinical-only. However, to conserve resources and meet study objectives, subjects with known pathogenic mutations will be given priority in selection for extensive clinical studies.~ 4. Direct blood relatives (typically parents and siblings) of affected individuals with NAFLD and associated conditions are also eligible to participate.~EXCLUSION CRITERIA:~1. Anyone unwilling to provide informed consent (for themselves as adults, or on behalf of their children as minors) or assent.~2. Pregnant women. Although fatty liver and cirrhosis are sometimes diagnosed during pregnancy, it is unclear if they were present before and just not diagnosed or if they develop as a complication of pregnancy. Additionally energy metabolism changes during pregnancy and lactation which may confound our analysis. If the condition persists after pregnancy and the diagnosis of NAFLD is~   clearly established, patients can be referred to the study.~3. We will review a clinical description from the referring physician about a potential research subject to determine that the subject is appropriate to enter into the study. We reserve the right to exclude cases that are clearly not NAFLD or related to our direct research interests (e.g. fatty liver induced by chronic alcohol use, infectious causes, drug-related, or toxin-related). This almost never happens. However, as some of these environmental factors may contribute to a multifactorial etiology of hepatic changes, we may not exclude all such cases.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NAFLD (Type: None): Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.
- NASH (Type: None): Patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes havebeen ruled out are eligible to participate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed renal cell carcinoma, including 1 of the following subtypes:~  * Clear cell~ * Papillary~ * Medullary~* Metastatic disease~* Not amenable to curative surgery~* No CNS metastases~PATIENT CHARACTERISTICS:~Performance status~* Karnofsky 70-100%~Life expectancy~* More than 6 months~Hematopoietic~* Not specified~Hepatic~* Bilirubin \< 2 times upper limit of normal (ULN)~* AST or ALT \< 4 times ULN~Renal~* Creatinine clearance \> 50 mL/min~Cardiovascular~* LVEF \> 35%~* No symptomatic congestive heart failure~Pulmonary~* DLCO \> 40% of predicted OR~* Total lung capacity or FEV_1 \> 30% of predicted~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 30 days since prior biologic therapy~Chemotherapy~* More than 30 days since prior chemotherapy~Radiotherapy~* More than 30 days since prior radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned bronchoscopy in relation to work-up after hemoptysis or other symptom leading to bronchoscopy~* Informed written consent~* Performance status 0-1~* Ct scan of thorax without suspicion of malignancy~* Weight t ≥ 60 og ≤ 130 kg~* Male gender or female gender in postmenopausal state defined by amenorrhea in more than 12 months.~Exclusion Criteria:~* Voriconazole treatment up to one week before inclusion~* Se-creatinin≥ 100 uM~* ALAT ≥ 70 U/l~* QT-interval \> 480 ms~* Allergic reaction to voriconazole or constituents in Vfend~* Allergic reaction to other azoles~* Ischemic Heart disease, Heart failure or uncontrolled hypertension~* Treatment with statins or omeprazole, which cannot be paused for three days during voriconazole exposure~* Treatment with Efavirenz, rifabutin, ritonavir, everolimus, methadon, alfentanil, fentanyl, sufentanil, oxycodone, hydrocodone, fluconazole, aztemizol, cisaprid, pimozid, quinidine, terfenadine, carbamazepine, phenobarbital, mephobarbital, ergotamine, dihydroergotamine, rifampicine, st. johns worth, everolimus, phenytoin, warfarin, phenprocoumon, acenocoumarol, benzodiazepines as midazolam, triazolam, alprazolam, sirolimus, cyclosporine, tacrolimus, ibuprofen, diclofenac,tolbutamide, glipizide, vincristine, vinblastine or other vinca alkaloids, HIV-protease Inhibitors e.g. saquinavir, amprenavir and nelfinavir, delavirdine, nivrapine and other non-nocleaoside revers transcriptase inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled voriconazole (Type: EXPERIMENTAL): 12 patients inhale voriconazole 40 mg b.i.d for two days
- Oral Voriconazole (Type: ACTIVE_COMPARATOR): 12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Newly Diagnosed Subjects~* The subject is male or female, aged 18 years of age or older~* The subject has a diagnosis of acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML); the subject must have a pathology-confirmed diagnosis~* The subject must have a pathology-confirmed diagnosis~* Acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML) is defined as having \>25% blasts in the bone marrow and/or peripheral blood~* The subject has not received any chemotherapy or treatment for their acute leukemia prior to the initial study visit~* The subject is able and willing to provide written informed consent~* The subject is able to understand the study and cooperate with all study instructions~Relapsed Subjects~* The subject is male or female, aged 18 years of age or older~* The subject has a diagnosis of relapsed acute lymphocytic leukemia (ALL) or relapsed acute myelogenous leukemia (AML)~* The subject must have a pathology-confirmed diagnosis~* Acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML) is defined as having ≥ 25% blasts in the bone marrow and/or peripheral blood~* The subject has received one or more of the pre-identified chemotherapeutic agents for treatment of their initial acute leukemia diagnosis~* The subject has not received any systemic chemotherapy or treatment for their relapsed acute leukemia~* Receipt of intrathecal chemotherapy will be permissible~* The subject is able and willing to provide written informed consent~* The subject is able to understand the study and cooperate with all study instructions~Exclusion Criteria:~* The subject has an uncontrolled serious medical or psychiatric illness that, in the opinion of the investigator, would compromise the subject's safety or collection of data~* The subject received treatment with an investigational drug within two weeks of the initial or subsequent study visits~* Subjects under the age of 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Myelodysplastic Syndrome by FAB. Can be made with cytogenetic analysis of Bone Marrow or Hematologist evaluation~* Patient must have had bone marrow biopsy and aspiration to confirm diagnosis within 60 days prior to treatment~* ECOG performance status of 0-2~* An EKG must be performed within 7 days prior to treatment to confirm QT interval \<460msec.~* Serum creatinine less than or equal to 2.5 times the upper limit of normal.~* Serum bilirubin less than or equal to 2.5 times the upper limit of normal.~* Serum potassium greater than or equal to 4.0 mEq/dL and serum magnesium greater than or equal to 1.8 mg/dL. If these serum electrolytes are below the specified limits on the baseline laboratory tests, electrolytes should be administered to bring the serum concentrations to these levels before administering arsenic trioxide.~* Patients must be 18 years of age to participate in this study~Exclusion Criteria:~* Pregnant or nursing women, and men or women of childbearing potential who are unwilling to employ adequate contraception.~* Corrected QT interval of greater than or equal to 460msec in the presence of serum potassium and magnesium values within normal range.~* Significant CHF, coronary is ischemia or serious Arrhythmias including conduction delays.~* Peripheral neuropathy greater than or equal to 2.~* Evidence of active infection~* Concurrent treatment with maintenance therapy, cytotoxic chemotherapy, radiation, or investigational agents.~* Inability or unwillingness to comply with the treatment protocol, follow up, or research tests.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Palovarotene for the Treatment of MO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written, signed, and dated informed subject/parent consent and age-appropriate assent (performed according to local regulations).~* A clinical diagnosis of MO with disease-causing exostosin 1 or 2 gene mutations.~* Male or female from 2 to 14 years of age.~* Female subjects must be premenarchal at screening.~* A bone age at screening of 14 years or less.~* Symptomatic MO, defined as five or more clinically evident osteochondromas and a new or enlarged osteochondroma that occurred in the preceding 12 months, five or more clinically evident osteochondromas and the presence of a painful osteochondroma, a skeletal deformity, a joint limitation, or prior surgery for a MO-related complication.~* The ability to undergo whole body MRI with or without sedation/general anesthesia.~* Use of two effective methods of birth control during treatment, and for 1 month after treatment discontinuation, unless committed to true abstinence from heterosexual sex. Sexually active females of child-bearing potential must also agree to start effective methods of birth control at screening.~Key Exclusion Criteria:~* Weight under 10 kg.~* Other syndromic conditions such as Langer-Giedion or Potocki-Shaffer.~* Any subject with neurologic signs suggestive of spinal cord impingement.~* Concomitant medications that are strong inhibitors or inducers of cytochrome P450 3A4 activity.~* Amylase or lipase \>2 times the above the upper limit of normal (\>2×ULN) or with a history of chronic pancreatitis.~* Elevated aspartate aminotransferase or alanine aminotransferase above 2.5×ULN.~* Any surgical implant that is contraindicated for MRI.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Palovarotene 2.5 mg daily regimen (Type: EXPERIMENTAL): None
- Palovarotene 5.0 mg daily regimen (Type: EXPERIMENTAL): None
- Placebo regimen (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Evidence Based Delivery Model of Care for Newly Implanted Adult CI Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are receiving a Nucleus® CI512, CI522, or CI532 electrodes~* 18 years and older~* Postlingual onset of hearing loss (onset of hearing loss \>two years of age)~* Individuals who qualify for cochlear implantation using the clinics current CI candidacy criteria~* Individuals who have recently been implanted but not yet had their external device activated~* Willingness to participate in a study and comply with all study requirements~* Fluent in spoken English~Exclusion Criteria:~* Ossification or any other cochlear anomaly that might prevent insertion of less than 10 electrodes of the electrode array~* Diagnosis of retro-cochlear pathology~* Diagnosis of auditory neuropathy~* Subject considering an acoustic component in the implanted ear~* Unrealistic expectations on the part of the subject regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure and use of the prosthetic device~* Unwillingness or inability to comply with all investigational requirements~* Severe-profound sensorineural hearing loss \>30 years~* Previous cochlear implant in the contralateral ear. Additional cognitive, medical or social handicaps that would prevent completion of all study requirements as determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A - New Model (Type: EXPERIMENTAL): Standardized programming and testing method
- Group B - Traditional Model (Type: ACTIVE_COMPARATOR): Traditional clinical model which is not standardized across clinical sites

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Use of Transdermal Clonidine in Trauma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ventilated male or female trauma patient 18 years of age or older admitted to the ICU \>24 hours~2. Patient must meet minimal medical criteria for potential extubation (meet criteria for being placed on spontaneous breathing trials per established MUMC SBT protocol)~3. Patients must exhibit delirium as assessed by the CAM-ICU assessment tool~4. Patient must be declared stable from a neurologic, respiratory and cardiovascular standpoint to receive clonidine by the attending MD~5. Consent must be obtained prior to any study procedures~Exclusion Criteria:~1. Patient \< 18 years old~2. Bradycardia (HR \< 60)~3. Presence of active pacemaker~4. Hypotensive (\<90/60)or active treatment of hypotension with vasoactive medications~5. Patient actively being treated with Clonidine or dexmedetomidine~6. Presence of allergy to Clonidine~7. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transdermal Clonidine/Oral Clonidine (Type: EXPERIMENTAL): An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
- Comparator (Type: PLACEBO_COMPARATOR): Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age \>/= 19 years~* diagnosed with CD for \>/= 6 months, currently in remission based on the Harvey-Bradshaw Index score (\</= 4 points) and C-reactive protein (\<5mg/L)~Exclusion Criteria:~* unable to provide informed consent;~* have significant hepatic, renal, endocrine, respiratory, neurological, or cardiovascular disease;~* confirmed diagnosis of celiac disease, or have suspected celiac disease and are following a gluten-free diet to manage symptoms with an elevated screening anti-tissue transglutaminase antibody test;~* significant complications of CD which includes a history of extensive colonic resection, including subtotal or total colectomy, history of \>/= 3 small bowel resections or received a diagnosis of short bowel syndrome, current ileostomy, colostomy or ileal-anal pouch, or a fixed symptomatic intestinal stenosis;~* antibiotic use in the 4 weeks prior to study start;~* use of any rectal preparations in the 2 weeks prior to study start;~* use of any non-steroidal anti-inflammatory drugs in the 2 weeks prior to study start;~* use of commercial probiotic supplements in the 4 weeks prior to study start~* change in CD therapy in the 4 weeks prior to study start (excluding steroid taper, however steroid dosing must be stable for 2 weeks prior to study start);~* recently been adhering to a novel dietary intervention for alternative health issues within the last 4 weeks prior to study start.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo muesli bars and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
- Moderate Oligosaccharide Group (Type: EXPERIMENTAL): 1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
- High Oligosaccharide Group (Type: EXPERIMENTAL): 1 intervention muesli bar and 1 serving intervention muesli per day (5.43 total fructans/GOS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Cervical Ripening With Orally Administered Misoprostol in Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Singleton gestation~2. Intact membranes~3. Bishop score \<= 4~4. Uterine contractions \<=12/hour~5. Cephalic presentation~6. Estimated gestational age of at least 38 weeks by ACOG dates~7. An amniotic fluid index (AFI) \>5 cm~8. Reactive Non Stress Test~9. Class A1, A2 diabetes~10. Good compliance with clinic visits and home glucose monitoring~Exclusion Criteria:~I. Fetal Factors~1. Multiple Gestation~2. Presence of fetal distress/non-reassuring FHR pattern~3. Malpresentation, including breech~4. EFW \> 4500 gm or other evidence of cephalo-pelvic disproportion~5. EFW \< 2000 gm~II. Maternal Factors~1. Frequent uterine contractions \>= 12/hour~2. Ruptured membranes~3. Placenta previa or unexplained vaginal bleeding~4. Vasa previa~5. Active herpes simplex~6. Glaucoma or elevated intraocular pressure~7. Renal or hepatic dysfunction~8. Previous Cesarean delivery or history of uterine surgery~9. Evidence of chorioamnionitis or maternal fetal \>= 100.4 degrees F~10. Significant cardiac lesion or cardiovascular disease~11. Severe asthma~12. Parity \>=6

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): patients will be treated with misoprostol 50 mcg PO
- 2 (Type: PLACEBO_COMPARATOR): patients will receive placebo (Vitamin C)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues